1151MO Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial

Authors :: Laurent Brouchet
B. Milleron
Olivier Molinier
M. Wislez
F. Le Pimpec Barthes
M.-A. Massiani
R. Caliandro
Martine Antoine
Diane Damotte
Virginie Westeel
O. Carre
J. Mazieres
T. Egenod
Gérard Zalcman
Alexandra Langlais
Radj Gervais
Armelle Lavolé
Jalal Assouad
Franck Morin
Gaelle Jeannin
Source :: Annals of Oncology. 32:S931
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Oncology
medicine.medical_specialty
Disease free survival
Durvalumab
business.industry
non-small cell lung cancer (NSCLC)
Pathological response
Hematology
medicine.disease
Independent factor
Internal medicine
medicine
Overall survival
business

Tools